- Conditions
- Glioblastoma
- Interventions
- Azeliragon, Temozolomide, Radiation therapy, Surgery or LITT
- Drug · Radiation · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 3,937
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HCV Infection
- Interventions
- ABT-072, ketoconazole, Placebo
- Drug · Other
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Waukegan, Illinois
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 347
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 265 more
- Conditions
- Pain, Pain, Postoperative
- Interventions
- cryoSPHERE Ablation, Bupivacaine
- Device · Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cannabis, Marijuana Abuse
- Interventions
- drug condition
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
- Interventions
- FT596, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab, Bendamustine
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 9
- States / cities
- Chicago, Illinois • Minneapolis, Minnesota • St Louis, Missouri + 5 more
- Conditions
- HIV
- Interventions
- Peer Mentoring Intervention
- Behavioral
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 5
- States / cities
- San Francisco, California • Miami, Florida • Baltimore, Maryland + 2 more
- Conditions
- Heart Failure Congestive
- Interventions
- Bumetanide, intranasal 4mg
- Drug
- Lead sponsor
- Prisma Health-Upstate
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Urinary Lithiasis, Kidney Diseases, Kidney Stone, Pain, Postoperative
- Interventions
- Toradol
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Recurrent Acute Otitis Media, Acute Otitis Media
- Interventions
- EarPopper
- Device
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 4 Years to 11 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- HIV
- Interventions
- Assays, HIV medical care, Social network and venue tracing, Community alerts, Community education, HIV counseling
- Other · Behavioral
- Lead sponsor
- National Development and Research Institutes, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Carbon Monoxide Measurement, Nicotine Lozenge, Oral Nicotine Pouch, Nicotine Patch, Survey Administration, Check-in Phone Calls
- Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Iliac Artery Stenosis
- Interventions
- Epic™ Nitinol Stent System, Anti-platelet therapy, Anti-coagulation therapy
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Brandon, Florida • Fort Lauderdale, Florida + 24 more
- Conditions
- HIV Infections
- Interventions
- CHECKIT!
- Other
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess Blasts, Refractory Anemia, De Novo Myelodysplastic Syndrome, Childhood Myelodysplastic Syndrome
- Interventions
- filgrastim, busulfan, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, umbilical cord blood transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 3 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Interventions
- Aripiprazole + IEM (Ingestible Event Marker)
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 4
- States / cities
- Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more
- Conditions
- Interaction
- Interventions
- Oregano, Drug cocktail
- Dietary Supplement · Drug
- Lead sponsor
- Washington State University
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Spokane, Washington
- Conditions
- Type 1 Diabetes
- Interventions
- FMPD AP algorithm, MPC AP system, Dexcom G6 Continuous Glucose Monitoring (CGM) System
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Growth
- Interventions
- Control Infant Formula, Control Toddler Drink, Experimental Infant Formula, Experimental Toddler Drink, Human Milk, Human Milk Supplemental Formula, Human Milk Toddler Drink
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 0 Days to 14 Days
- Enrollment
- 607 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Glenwood, Arkansas • Hot Springs, Arkansas + 35 more
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged, Refractory Acute Myeloid Leukemia Due to Lineage Switch From Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol, Cytarabine, Echocardiography Test, Electrocardiogram, Fludarabine Phosphate, Hydrocortisone Sodium Succinate, Lumbar Puncture, Methotrexate, Multigated Acquisition Scan, Prednisolone, Prednisone, Revumenib, Vincristine Sulfate
- Procedure · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Month to 6 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 60 more
- Conditions
- Substance Use Disorder
- Interventions
- Computerized brief intervention, Computerized health screening, Computerized assessment, Therapist-delivered motivational intervention
- Behavioral
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 713 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Substance Use, Delinquency
- Interventions
- Multidimensional Family Therapy (MDFT), Adolescent Residential Treatment
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2010
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Consolidation Therapy, Functional Magnetic Resonance Imaging, Gastrointestinal Endoscopy, Magnetic Resonance Imaging, Papaverine, Radiation Therapy, Total Mesorectal Excision
- Procedure · Drug · Radiation
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
- Interventions
- vandetanib, placebo, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, pharmacological study
- Drug · Other · Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois